Neuraminidase Inhibitor Resistance Uncommon with Latest Pandemic Influenza A Strain

Although little NAI resistance was seen in the most-recent pandemic influenza A strain (H1N1pdm2009), it was detected in a few patients — mainly young children — after oseltamivir treatment.

Ever since influenza A viruses developed widespread resistance to adamantanes, the neuraminidase inhibitors (NAIs) osteltamivir and zanamivir have been the primary therapies. During the 2007–2008 influenza season, naturally occurring oseltamivir resistance associated with the H275Y neuraminidase mutation emerged among seasonal influenza A (H1N1) viruses. However, the affected strain was replaced in 2009 by H1N1pdm2009, which is typically oseltamivir susceptible.

Now, researchers have published the results of an industry-funded, prospective, multinational, observational study, conducted from December 2008 to March 2011, to detect and monitor the frequency of viral resistance to NAIs. A total of 1799 individuals with virologically confirmed in…

Reviewing Author

Neil M. Ampel, MD

Disclosures

Editorial BoardsUpToDate

Leadership Positions in Professional SocietiesCoccidioidomycosis Study Group (Past President, Secretary, Treasurer)

Neil M. Ampel, MD

Disclosures

Editorial BoardsUpToDate

Leadership Positions in Professional SocietiesCoccidioidomycosis Study Group (Past President, Secretary, Treasurer)

Neuraminidase Inhibitor Resistance Uncommon with Latest Pandemic Influenza A Strain

Topics

Reviewing Author